KR20220018512A - 신경 변성 질환에 대한 atp 증강 요법의 효과를 예측하는 방법 - Google Patents

신경 변성 질환에 대한 atp 증강 요법의 효과를 예측하는 방법 Download PDF

Info

Publication number
KR20220018512A
KR20220018512A KR1020217043096A KR20217043096A KR20220018512A KR 20220018512 A KR20220018512 A KR 20220018512A KR 1020217043096 A KR1020217043096 A KR 1020217043096A KR 20217043096 A KR20217043096 A KR 20217043096A KR 20220018512 A KR20220018512 A KR 20220018512A
Authority
KR
South Korea
Prior art keywords
atp
hypoxanthine
disease
enhancing therapy
therapy
Prior art date
Application number
KR1020217043096A
Other languages
English (en)
Korean (ko)
Inventor
나오유키 가마타니
Original Assignee
가부시키가이샤 스타젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 스타젠 filed Critical 가부시키가이샤 스타젠
Publication of KR20220018512A publication Critical patent/KR20220018512A/ko

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020217043096A 2019-06-07 2020-06-05 신경 변성 질환에 대한 atp 증강 요법의 효과를 예측하는 방법 KR20220018512A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019106792A JP7333942B2 (ja) 2019-06-07 2019-06-07 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法
JPJP-P-2019-106792 2019-06-07
PCT/JP2020/022219 WO2020246564A1 (ja) 2019-06-07 2020-06-05 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法

Publications (1)

Publication Number Publication Date
KR20220018512A true KR20220018512A (ko) 2022-02-15

Family

ID=73652238

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217043096A KR20220018512A (ko) 2019-06-07 2020-06-05 신경 변성 질환에 대한 atp 증강 요법의 효과를 예측하는 방법

Country Status (3)

Country Link
JP (1) JP7333942B2 (ja)
KR (1) KR20220018512A (ja)
WO (1) WO2020246564A1 (ja)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017033963A1 (ja) 2015-08-26 2017-03-02 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2018092911A1 (ja) 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521451A (ja) * 1998-07-31 2002-07-16 エイチエムイー エンタープライゼズ，リミテッド ライアビリティ カンパニー 抗酸化物質組成物及び該組成物を用いて疾患を処理する方法
JP6875683B2 (ja) * 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
IT201600109735A1 (it) * 2016-10-31 2018-05-01 Giuseppe Lazzarino Biomarcatori e metodi per la diagnosi in vitro di sclerosi multipla.
JP6937134B2 (ja) * 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
JP6966840B2 (ja) * 2017-01-24 2021-11-17 株式会社スタージェン 神経変性疾患の改善用医薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017033963A1 (ja) 2015-08-26 2017-03-02 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2018092911A1 (ja) 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1: Wilkins HM, Morris JK. New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders. Curr Pharm Des. 2017; 23(5): 731-752.
비특허문헌 10: Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X(2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842: 1240-1247
비특허문헌 11: Perez MJ, Ponce DP, Osorio-Fuentealba C, Behrens MI, Quintanilla RA. Mitochondrial Bioenergetics Is Altered in Fibroblasts from Patients with Sporadic Alzheimer's Disease. Front Neurosci. 2017 Oct 6; 11: 553.
비특허문헌 12: Pera M, Larrea D, Guardia-Laguarta C, Montesinos J, Velasco KR, Agrawal RR, Xu Y, Chan RB, Di Paolo G, Mehler MF, Perumal GS, Macaluso FP, Freyberg ZZ, Acin-Perez R, Enriquez JA, Schon EA, Area-Gomez E. Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J. 2017 Nov 15; 36(22): 3356-3371.
비특허문헌 13: Desler C, Lillenes MS, Tonjum T, Rasmussen LJ. The role of mitochondrial dysfunction in the progression of Alzheimer's disease. Curr Med Chem. 2017 Jun 16. doi: 10.2174/0929867324666170616110111.
비특허문헌 14: Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, Parker WD Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 1996, 40: 663-71.
비특허문헌 15: Prestia FA, Galeano P, Martino Adami PV, Do Carmo S, Castano EM, Cuello AC, Morelli L. Platelets Bioenergetics Screening Reflects the Impact of Brain Aβ Plaque Accumulation in a Rat Model of Alzheimer. Neurochem Res. 2018 Oct 24. doi: 10.1007/s11064-018-2657-x.
비특허문헌 16: Nakano M, Imamura H, Sasaoka N, Yamamoto M, Uemura N, Shudo T, Fuchigami T, Takahashi R, Kakizuka A. ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease. EBioMedicine. 22: 225-241, 2017
비특허문헌 17: Kamatani N, Hashimoto M, Sakurai K, Gokita K, Yoshihara J, Sekine M, Mochii M, Fukuuchi T, Yamaoka N, Kaneko K. Clinical studies on changes in purine compounds in blood and urine by the simultaneous administration of febuxostat and inosine, or by single administration of each. Gout and Nucleic Acid Metabolism 41, 171-181, 2017.(https://www.jstage.jst.go.jp/article/gnam/41/2/41_171/_pdf/-char/ja)
비특허문헌 18: Kamatani N, Kushiyama A, Toyo-Oka L, Toyo-Oka T. Treatment of two mitochondrial disease patients with a combination of febuxostat and inosine that enhances cellular ATP. J Hum Genet. 2019; 64: 351-353.
비특허문헌 19: Johnson TA, Jinnah HA and Kamatani N. Shortage of cellular ATP as a cause of diseases and strategies to enhance ATP. Front Pharmacol. 2019 Feb 19; 10: 98. https://www.frontiersin.org/articles/10.3389/fphar.2019.00098/full
비특허문헌 2: Deng J, Wang P, Chen X, Cheng H, Liu J, Fushimi K, Zhu L, Wu JY. FUS interacts with ATP synthase beta subunit and induces mitochondrial unfolded protein response in cellular and animal models. Proc Natl Acad Sci USA. 2018 Oct 9; 115(41): E9678-E9686.
비특허문헌 20: Linder N, Rapola J, Raivio KO. Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest. 1999 Aug; 79(8): 967-74.
비특허문헌 21: Suzuki G, Okamoto K, Kusano T, Matsuda Y, Fuse A, Yokota H. Evaluation of neuronal protective effects of xanthine oxidoreductase inhibitors on severe whole-brain ischemia in mouse model and analysis of xanthine oxidoreductase activity in the mouse brain. Neurol Med Chir(Tokyo). 2015; 55(1): 77-85.
비특허문헌 22: Yamaguchi M, Okamoto K, Kusano T, Matsuda Y, Suzuki G, Fuse A, Yokota H. The Effects of Xanthine Oxidoreductase Inhibitors on Oxidative Stress Markers following Global Brain Ischemia Reperfusion Injury in C57BL/6 Mice. PLoS One. 2015 Jul 31; 10(7): e0133980.
비특허문헌 23: Spector R. Hypoxanthine transport through the blood-brain barrier. Neurochem Res. 1987 Sep; 12(9): 791-6.
비특허문헌 24: Redzic ZB, Gasic JM, Segal MB, Markovic ID, Isakovic AJ, Rakic MLj, Thomas SA, Rakic LM. The kinetics of hypoxanthine transport across the perfused choroid plexus of the sheep. Brain Res. 2002 Jan 25; 925(2): 169-75.
비특허문헌 25: Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF, Bogdanov M. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One. 2009 Oct 22; 4(10): e7551.
비특허문헌 26: Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, Weinstein G, Wang TJ, Gerszten RE, Vasan RS, Seshadri S. Association of amine biomarkers with incident dementia and Alzheimer's disAlzheimers Dement. 2017 13: 1327-1336.
비특허문헌 27: Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH; Alzheimer's Disease Neuroimaging Initiative. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline? Eur J Neurol. 2016 May; 23(5): 948-57.
비특허문헌 28: Lu N, Dubreuil M, Zhang Y, Neogi T, Rai SK, Ascherio A, Hernan MA, Choi HK. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016 Mar; 75(3): 547-51.
비특허문헌 29: Al-khateeb E, Althaher A, Al-khateeb M, Al-Musawi H, Azzouqah O, Al-Shweiki S, Shafagoj Y. Relation between uric acid and Alzheimer's disease in elderly Jordanians. J Alzheimers Dis. 2015; 44(3): 859-65.
비특허문헌 3: Nakaya T, Maragkakis M. Amyotrophic Lateral Sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci Rep. 2018 Oct 22; 8(1): 15575.
비특허문헌 30: Chen X, Guo X, Huang R, Chen Y, Zheng Z, Shang H. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One. 2014 Apr 8; 9(4): e94084.
비특허문헌 31: Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010; 19(4): 1331-6.
비특허문헌 32: Tohgi H, Abe T, Takahashi S, Kikuchi T. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993; 6(2): 119-26.
비특허문헌 33: Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6): 716-23.
비특허문헌 34: Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007 Oct 23; 69(17): 1696-700.
비특허문헌 35: McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neurodegener Dis. 2013; 12(4): 189-98.
비특허문헌 36: Parkinson Study Group SURE-PD Investigators, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2): 141-50.
비특허문헌 37: Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, Wurster I, Schleicher E, Melms A, Berg D. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway. J Alzheimers Dis. 2011; 27(1): 119-26.
비특허문헌 38: Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics. 2016 Dec 19.[Epub ahead of print]
비특허문헌 39: Wang L, Hu W, Wang J, Qian W, Xiao H. Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. Mult Scler Relat Disord. 2016 Sep; 9: 17-22.
비특허문헌 4: Panchal K, Tiwari AK. Mitochondrial dynamics, a key executioner in neurodegenerative diseases. Mitochondrion. 2018 Nov 5. pii: S1567-7249(18)30120-X.
비특허문헌 40: Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013 Jun 6; 153(6): 1194-217.
비특허문헌 41: Tuite P. Brain Magnetic Resonance Imaging(MRI) as a Potential Biomarker for Parkinson's Disease(PD). Brain Sci. 2017 Jun 16; 7(6). pii: E68.
비특허문헌 42: Franco-Iborra, S.; Vila, M.; Perier, C. The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? Neuroscientist 2015.
비특허문헌 43: Diebold, L., and Chandel, N. S.(2016). Mitochondrial ROS regulation of proliferating cells. Free Radic. Biol. Med. 100, 86-93. doi: 10.1016/j.freeradbiomed.2016.04.198
비특허문헌 44: Scialo F., Sriram, A., Fernandez-Ayala, D., Gubina, N., Lohmus, M., Nelson, G., et al.(2016). Mitochondrial ROS produced via reverse electron transport extend animal lifespan. Cell Metab. 23, 725-734. doi: 10.1016/j.cet.2016.03.009
비특허문헌 45: Quijano, C., Trujillo, M., Castro, L., and Trostchansky, A.(2016). Interplay between oxidant species and energy metabolism. Redox Biol. 8, 28-42. doi: 10.1016/j.redox.2015.11.010
비특허문헌 46: Hellsten, Y., Richter, E. A., Kiens, B., and Bangsbo, J.(1999). AMP deamination and purine exchange in human skeletal muscle during and after intense exercise. J. Physiol. 520(Pt 3), 909-920. doi: 10.1111/j.1469-7793.1999.00909.x
비특허문헌 47: Donderski, R., Miskowiec-Wisniewska, I., Kretowicz, M., Grajewska, M., Manitius, J., Kaminska, A., et al.(2015). The fructose tolerance test in patients with chronic kidney disease and metabolic syndrome in comparison to healthy controls. BMC Nephrol. 16:68. doi: 10.1186/s12882-015-0048-y
비특허문헌 48: Lieber, C. S.(1965). Hyperuricemia induced by alcohol. Arthritis Rheum. 8, 786-798. doi: 10.1002/art.1780080442
비특허문헌 49: Beberashvili, I., Erlich, A., Azar, A., Sinuani, I., Feldman, L., Gorelik, O., et al.(2016). Longitudinal study of serum uric acid, nutritional status, and mortality in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 11, 1015-1023. doi: 10.2215/CJN.10400915
비특허문헌 5: Champy P, Hoglinger GU, Feger J, Gleye C, Hocquemiller R, Laurens A, Guerineau V, Laprevote O, Medja F, Lombes A, Michel PP, Lannuzel A, Hirsch EC, Ruberg M(Jan 2004). "Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe". J neurochem 88(1): 63-69
비특허문헌 50: Beberashvili, I., Sinuani, I., Azar, A., Shapiro, G., Feldman, L., Stav, K., et al.(2015). Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients. Nutrition 31, 138-147. doi: 10.1016/j.nut.2014.06.012
비특허문헌 51: Jimenez, M. L. et al. Hypoxanthine and xanthine transport through the blood-brain barrier in hypoxanthine phosphoribosyltransferase(HPRT) deficiency. Adv Exp Med Biol 253 A, 173-179(1989).
비특허문헌 52: Redzic ZB, Gasic JM, Segal MB, Markovic ID, Isakovic AJ, Rakic MLj, Thomas SA, Rakic LM. The kinetics of hypoxanthine transport across the perfused choroid plexus of the sheep. Brain Res. 2002 Jan 25; 925(2): 169-75
비특허문헌 53: Fukuuchi, T., Yamaoka, N. & Kaneko, K. Analysis of Intra-and Extracellular Levels of Purine Bases, Nucleosides, and Nucleotides in HepG2 Cells by High-performance Liquid Chromatography. Anal Sci 31, 895-901(2015).
비특허문헌 6: Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. The EMBO Journal. 2012; 31: 3038-3062
비특허문헌 7: Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD(2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106: 14670-14675
비특허문헌 8: Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS(2010) Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107: 18670-18675
비특허문헌 9: Swerdlow RH, Burns JM, Khan SM(2014) The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta 1842: 1219-1231

Also Published As

Publication number Publication date
JP2020201068A (ja) 2020-12-17
WO2020246564A1 (ja) 2020-12-10
JP7333942B2 (ja) 2023-08-28

Similar Documents

Publication Publication Date Title
Gardner et al. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders
Grünert et al. Clinical and neurocognitive outcome in symptomatic isovaleric acidemia
US9034299B2 (en) ATF4 inhibitors and their use for neural protection, repair, regeneration, and plasticity
Smach et al. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer’s disease or dementia: a case control study
Mouton-Liger et al. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease
Wu et al. The characteristics of the stone and urine composition in Chinese stone formers: primary report of a single-center results
US9211294B2 (en) Phenothiazine compounds for treating mild cognitive impairment
Yang et al. Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation
Annerbo et al. The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer’s disease in mild cognitive impairment: a 6-year follow-up study
US20080125404A1 (en) Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
ES2731678T3 (es) Herramientas de diagnóstico para la enfermedad de Alzheimer
US20230038724A1 (en) Method and compositions for the treatment of anemia through the inhibition of furin
Watson et al. Resolution of acyclovir‐associated neurotoxicity with the aid of improved clearance estimates using a Bayesian approach: A case report and review of the literature
Park et al. Plasma neutrophil gelatinase-associated lipocalin as an early predicting biomarker of acute kidney injury and clinical outcomes after recovery of spontaneous circulation in out-of-hospital cardiac arrest patients
WO2005070079A2 (en) Methods of using zonisamide as an adjunctive therapy for partial seizures
Thomas et al. Buccal cytome biomarkers and their association with plasma folate, vitamin B12 and homocysteine in Alzheimer's disease
Akın et al. Current medical treatment in pediatric urolithiasis
JP6867142B2 (ja) パーキンソン症状改善用医薬
US20150374676A1 (en) Helicase-primase inhibitors for use in a method of treating alzheimer's disease
Cains et al. Addressing a folate imbalance in fetal cerebrospinal fluid can decrease the incidence of congenital hydrocephalus
WO2005070078A2 (en) Methods of using zonisamide as an adjunctive therapy for partial seizures
Qureshi et al. The neurochemical markers in cerebrospinal fluid to differentiate between aseptic and tuberculous meningitis
JP7333942B2 (ja) 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法
Saleem et al. Role of plasma amino acids profiles in pathogenesis and prediction of severity in patients with drug resistant epilepsy
Forloni Oligomers and neurodegeneration: new evidence